Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
CLNN
CLNN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CLNN News
Clene Inc. Outlines Key Milestones for 2026
Feb 24 2026
Yahoo Finance
Clene Inc. to Present at Emerging Growth Conference on January 21, 2026
Jan 16 2026
Globenewswire
Clene Inc. to Present at Emerging Growth Conference on January 21, 2026
Jan 16 2026
Newsfilter
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
Jan 14 2026
NASDAQ.COM
Clene Inc. Receives FDA Approval for In-Person Meeting in 2026, NfL Reductions Linked to Lower ALS Mortality Risk
Jan 12 2026
Globenewswire
Clene Inc. Receives FDA Approval for In-Person Meeting in 2026, NfL Reduction Significantly Lowers ALS Mortality Risk
Jan 12 2026
Newsfilter
Clene Inc. Secures $28 Million Financing to Advance ALS Drug Development
Jan 09 2026
Globenewswire
Clene Insider Offloads Shares Valued at $1,725,735, Per Recent SEC Filing
Dec 18 2025
Yahoo Finance
88th Emerging Growth Conference Scheduled for December 10-11, 2025
Dec 10 2025
Globenewswire
Clene Set to Deliver Important Update on CNM-Au8 for Amyotrophic Lateral Sclerosis
Dec 03 2025
NASDAQ.COM
Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain
Dec 03 2025
NASDAQ.COM
Clene Inc. to Update ALS Treatment Progress on December 3, 2025
Dec 02 2025
Globenewswire
Clene Inc. to Update ALS Treatment Progress on December 3, 2025
Dec 02 2025
Newsfilter
D. Boral Capital Reiterates Buy Rating on Clene with $23 Price Target Intact
Nov 17 2025
Benzinga
D. Boral Capital Reiterates Buy Rating on Clene with $23 Price Target Intact
Oct 24 2025
Benzinga
Clene Unveils New Clinical Findings at ECTRIMS 2025 Meeting Showing CNM-Au8® Enhances Brain Energy Metabolism in Patients with Multiple Sclerosis
Sep 25 2025
Newsfilter
Show More News
